Pepteon Academy
Pepteon Academy Clinical Education · Licensed Prescribers

Non-Responder Decision Algorithm

Non-Responder Decision Algorithm

Structured pathway for GLP-1 weight-management patients who do not achieve clinically meaningful weight loss at 16 weeks.

Draft — requires medical reviewer signoff

This protocol is a draft requiring licensed-physician review before clinical application.

Defining Non-Response

Response category Threshold at 16 weeks Action
Super-responder ≥15% weight loss Continue. Consider dose maintenance over escalation.
Good responder 8–15% weight loss Continue current regimen. Complete titration if not at max.
Partial responder 5–8% weight loss Continue with lifestyle intensification; consider GH secretagogues for lean mass.
Non-responder <5% weight loss Enter the decision algorithm below.
Severe non-responder <2% weight loss Faster decision; consider class switch earlier.

Pre-Switch Checklist — Rule Out Confounders

Before declaring non-response, verify:

  1. Adherence — actual medication uptake
  2. Titration completion — at max-tolerated dose for ≥8 weeks
  3. Confounding medications — SSRIs, atypical antipsychotics (mirtazapine, olanzapine), anticonvulsants (pregabalin)
  4. Sleep — undiagnosed OSA (STOP-BANG screen)
  5. Mental health — depression + binge eating disorder (PHQ-9, EDE-Q)
  6. Thyroid — recheck TSH
  7. Cortisol — rule out Cushing features
  8. Caloric intake — paradoxical under-eating
  9. Resistance training — without stimulus, body composition plateaus
  10. Protein intake — below 1.2 g/kg body weight

~40% of apparent non-responders resolve with confounder correction.

Algorithm

flowchart TD
    A[16-week assessment: <5% loss] --> B{At max tolerated dose ≥8 weeks?}
    B -->|No| C[Complete titration<br/>Reassess]
    B -->|Yes| D{Confounders present?}
    D -->|Yes| E[Address confounders first]
    D -->|No| F{Current agent}
    F -->|Semaglutide| G[Switch to tirzepatide]
    F -->|Tirzepatide| H{BMI ≥40 or ≥35 + comorbidity?}
    H -->|Yes| I[Bariatric surgery consult]
    H -->|No| J[Add lean-mass stack<br/>Consider Tesamorelin]

Class Switch — Semaglutide → Tirzepatide

Evidence supports tirzepatide achieving weight loss in semaglutide non-responders. Different receptor profile (GIP + GLP-1 vs. GLP-1 alone) means non-response to one does not predict non-response to the other.

Approach:

  • Hold semaglutide
  • 2–4 week washout optional
  • Start tirzepatide at 2.5 mg per FDA titration
  • Reassess at 16 weeks

Related Peptides

Related Conditions

Supporting Evidence

Claim Source PMID Evidence Level
~10-15% non-response rate at 16 weeks on GLP-1 STEP 1 subgroup analysis 33567185 I
Tirzepatide achieves response post-semaglutide exposure SURMOUNT-1 35658024 I
Weight regain magnitude on discontinuation STEP 4 / SURMOUNT-4 33755728 / 38078870 I

Referenced in: Module 5 Lesson 5.8